Request Discount

RNAi Therapeutics Market (Type - Small Interfering RNAs (siRNA), and MicroRNA (miRNA); Application - Genetic Disorders, Oncology, Neurodegenerative Disorders, Infectious Diseases, Renal Diseases, and Others; Route of Administration - Intradermal Injections, Pulmonary Delivery, and Intravenous Injections; End User - Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

  • Published : February, 2022

  • Rep Id : HC08734

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the RNAi therapeutics market provides in-depth analysis of segments and sub-segments in the global as well as regional RNAi therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional RNAi therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global RNAi therapeutics market. According to the report, the global RNAi therapeutics market is projected to reach USD 1163 million by 2027 from USD 705 million in 2021, growing with a CAGR of 9% over the forecast period of 2021-2027.

 

Market Insight

A biological process in which target mRNA molecules are neutralized and RNA molecules are observed to inhibit gene expression or translation is known as RNA interference. It is a collection of small RNA-directed mechanisms which result in sequential-specific inhibition of genetic expression. Many investigators adopted the idea that RNAi could immediately bring a new class of treatment; hence, it has been experimented with very quickly from the laboratory to the bedside. Furthermore, the RNAi approach is widely used for drug development and clinical trials under development in several phases. Moreover, RNAi therapy makes it possible to calm specific and highly effective genes by providing an opportunity to alter the expression of genes; hence it is considered an effective therapy for targeting rib nucleotide seeds (RNA). RNAi found applications in oncology, cardiovascular diseases, respiratory disorders, kidney diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others. The RNAi process becomes beneficial for many end-users because it inhibits the ability of disease proteins to cause disease. Notably, the RNAi process was awarded the Nobel Prize in 2006, due to which it had a significant impact on the pharmaceutical sector.

 

There are many collaborations between drug distribution companies and contract research organizations (CROs), which are adding to the growth of the global RNAi therapeutic market. For instance, Ionis Pharmaceuticals collaborated with GSK Pharmaceuticals and initiated a Phase-I study of ISIS-HBV-L Rx to treat Hepatitis B viral infection. Furthermore, due to the rising deaths of people by cancer, there is an increased awareness among citizens and the adoption of RNAi therapeutics in the market. Moreover, the primary driver of the market is advancement in drug delivery technology which can treat rare and chronic diseases. Additionally, an increase in R&D to treat chronic diseases plays a significant role in the RNAi market’s growth. Also, it is expected that the successful clinical trials of pipeline products will expand the market soon, hence helping the market’s growth. However, the significant factors that hamper the market’s growth are a high investment, strict regulations, distribution of RNAi drugs for tissue specification, and others. Furthermore, the high cost of R&D is controlling the market and hampering the market’s growth. Additionally, in many developing countries, there is an inadequate infrastructure of health services which leads the market to a high risk of failure, a lack of skilled professionals in drug control laboratories, and a lack of RNAi therapeutic appropriate distribution network, which can negatively impact the market. Nevertheless, the public institutions are focusing on R&D work on nanotechnology, which is expected to create a tremendous growth opportunity for to market in the forecast period.

 

The RNAi therapeutics market is segmented into North America, Europe, Asia Pacific, and the rest of the world. The North American region is expected to hold the largest share of the global RNAi therapeutics market and dominate the market during the forecast period. There are rising pharmaceutical investments in the region, due to which the demand for the market is higher. Furthermore, the growing research activity in gene therapy, immunotherapy, and cell therapy treatments is expected to demand RNAi drugs during the forecast period. The market sales from the Asia Pacific region are expected to increase during the forecast period due to several factors like increasing healthcare expenditure, the high adoption rate of new technologies, and others. Additionally, there are prominent market players currently active in the region; hence the demand for RNAi therapeutics is expected to rise during the forecast period. In Europe, cancer cases have increased over the past few years. Vast research activity in gene therapy and immunotherapy treatments is ongoing in the region. These research activities have created a magnificent demand for RNAi drugs in clinics across the globe, which is anticipated to drive the market’s growth in the Europe region.

 


RNAi Therapeutics Market


Segment Covered

The report on the global RNAi therapeutics market covers segments such as type, application, route of administration, and end user. On the basis of type, the sub-markets include small interfering RNAs (siRNA), and microRNA (miRNA). On the basis of application, the sub-markets include genetic disorders, oncology, neurodegenerative disorders, infectious diseases, renal diseases, and others. On the basis of route of administration, the sub-markets include intradermal injections, pulmonary delivery, and intravenous injections. On the basis of end user, the sub-markets include diagnostic laboratories, research and academic laboratories, and hospitals.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Quark, and Others.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the RNAi therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount